Bergen Open Research Archive >
Faculty of Medicine >
Institute of Medicine >
Section for Rheumatology >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/1956/2637
|
| Title: | Calprotectin (S100A8/A9) and S100A12 in inflammatory arthritis : clinical and epidemiological studies of rheumatoid and psoriatic arthritis |
| Authors: | Madland, Tor Magne |
| Issue Date: | 14-Dec-2007 |
| Publisher: | The University of Bergen |
| Abstract: | Rheumatoid- and psoriatic arthritis (RA and PsA) are the two most prevalent
inflammatory joint diseases in Caucasian. Different biomarkers in peripheral blood
may contribute in the diagnostic and prognostic process, as well as in assessing the
disease activity of the individual patient. The concentration of the leukocyte protein
complex calprotectin (S100A8/A9) is increased in inflamed joints and in peripheral
blood of patients with various inflammatory diseases. S100A12 is another S100
protein that more recently has been described as a proinflammatory protein in
arthritis. Disease manifestations and prognosis in RA and PsA have both articular and
non-articular aspects, and these should be adressed during treatment of the patients.
The risk of cardiovascular disease is increased in RA, and to a lesser extent in PsA.
Supplementation with fish oil has modest beneficial effects in RA both for arthritis
and collateral health.
The overall aim of the study was to investigate calprotectin and S100A12 as
biomarkers of disease activity or distinct clinical features in patients with either RA
or PsA. In addition, we wanted to estimate the prevalence of PsA in our population
and to explore effects of short-term oral supplementation with seal oil.
We found a prevalence of PsA in the county of Hordaland equivalent to 1.95 per
1000. If given a prevalence of psoriasis at 1.4%, this corresponds to a PsA prevalence
among psoriatics of 14%. The levels of calprotectin were elevated in stool samples
from patients with PsA, suggesting asymptomatic psoriatic enteropathy. In a clinical
trial with seal oil to patients with PsA we found improvement in subjective measures
and a significant shift in the fatty acid composition in peripheral blood, toward a
putative antiinflammatory profile. We found that both calprotectin and S100A12
levels in serum correlate with disease activity parameters in RA. High levels of
S100A12 were detected in patients with RA, as well as new conformational states of
this protein. The S100 proteins did not perform better than CRP as inflammatory. |
| URI: | http://hdl.handle.net/1956/2637 |
| ISBN: | 978-82-308-0472-8 (print version) |
| Appears in Collections: | Section for Rheumatology
|
Items in BORA are protected by copyright, with all rights reserved, unless otherwise indicated.
